Opinion on Pharmaceuticals in North America

Published within

« | ... | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Plant vaccines: growing closer to commercial reality

Transgenic plant technologies could lead to a revolution in vaccine production and manufacture. Should plant-based vaccines prove effective in clinical trials, this will drive licensing activity between key vaccine players and companies with relevant intellectual property.

Published By Datamonitor
20 Aug 2003
CommentWire
CommentWire

Ulcer drugs: generic launches threaten branded market

Novartis [NVS] has joined Mylan [MYL] and Schwarz [SRZG.F] in offering a generic version of blockbuster ulcer drug Prilosec in the US. The arrival of Novartis may open the floodgates for multiple generics in the ulcer drug market. Yet for companies launching generics before legal issues are settled, the risks are huge.

Published By Datamonitor
27 Aug 2003
CommentWire
CommentWire

Schering-Plough: cancer can cure its woes

Schering-Plough [SGP] faces increasing competition in markets it used to dominate, such as hepatitis C and allergic rhinitis. The company has attempted to reverse this trend by moving into alternative franchises such as oncology. Schering-Plough may seek to complement its organic growth by partnering with a company that has expertise in this area.<BR />

Published By Datamonitor
27 Aug 2003
CommentWire
CommentWire

Johnson & Johnson: fat figures and slimmer waistlines

Recent evidence has shown that Johnson & Johnson's [JNJ] Topamax promotes weight loss in obese patients with type II diabetes. The drug is currently used to treat epilepsy although it has shown potential for a number of indications in clinical studies. The company hopes to boost Topamax sales further by penetrating a difficult but potentially lucrative market.<BR />

Published By Datamonitor
29 Aug 2003
CommentWire
CommentWire

Antibiotics: use drops among US children

A new study has reported a substantial decrease in pediatric antibiotic prescriptions between 1996 and 2000. The development shows the success of a wider campaign to reduce overuse of antibiotics - a serious problem that contributes to the development of disease-resistant forms of common bacteria.

Published By Datamonitor
04 Sep 2003
CommentWire
CommentWire

GlaxoSmithKline: bad week on two fronts

GSK's [GSK.L] Ariflo has failed to demonstrate effectiveness in Chronic Obstructive Pulmonary Disease (COPD). Meanwhile, GSK's antidepressant blockbuster Paxil is under threat from generic competition, which will inevitably reduce its market share. Efforts to strengthen the brand will not offset the sales loss.

Published By Datamonitor
11 Sep 2003
CommentWire
CommentWire

Ulcer drugs: challenges in store

Procter & Gamble's [PG] launch of Prilosec OTC will have wide-ranging effects on the market for heartburn and ulcer drugs. The availability of an OTC alternative is leading US insurance companies to restrict access to competing prescription drugs. Although generic OTC omeprazole will not be available for several years, PPI companies must find successor products to protect their franchises.

Published By Datamonitor
22 Sep 2003
CommentWire
CommentWire

Pancreatic cancer: vaccine gives new hope

Researchers at the Memorial Sloan-Kettering Cancer Center in the US have reported promising results for a pancreatic cancer vaccine developed using proteins from the patient's own tumor. Although preliminary results appear encouraging, it will be some time before patients can gain access to the drug.

Published By Datamonitor
23 Sep 2003
CommentWire
CommentWire

Novartis: Prexige delay proving painful

The FDA has requested the submission of Novartis' [NVS] TARGET study report as well as additional clinical data for COX-II inhibitor Prexige. Delayed entry into the already saturated COX-II inhibitor market is bad news for the Swiss company, which hopes to capture market share from leaders Pfizer [PFZ.L] and Merck & Co [MRK].

Published By Datamonitor
29 Sep 2003
CommentWire
CommentWire

Pfizer: Inspra to be a cardio blockbuster

The approval of Pfizer's [PFE] Inspra (eplerenone) for post-MI heart failure patients, based on the EPHESUS trial results, should be sufficient for use of the drug to exceed that of its less well tolerated predecessor, spironolactone. With marketing support from Pfizer, Inspra is all set for blockbuster status.

Published By Datamonitor
13 Oct 2003

« | ... | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | ... | » »|

No help is available.